# Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen

> **NCT00191269** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 68 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** gemcitabine
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00191269
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2008-03
- **Final completion:** 2010-03
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2010-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191269, "Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00191269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*